The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

June 8 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of ...

The new expansion covers all patients 6 and older, regardless of their inhibitor status. The new nod also opens up the ...

Vertex Pharmaceuticals announced the FDA has accepted its biologics license application submission for povetacicept, an ...

Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda ...

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.

At a big meeting for weight loss drugs, Lilly’s “triple G” therapy set a new standard as lingering doubts surrounded other ...

Pfizer is an over-100-year-old drug company going through a rough patch, which has happened before.

With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising ...

Durability, not yield, is the deciding factor.

Pfizer is racing towards patent cliffs that will lead to even worse financial results. Vertex Pharmaceuticals is posting strong revenue growth and excellent clinical progress. As a result, Vertex ...

Pharmaceutical stocks can be excellent defensive investments during times of economic uncertainty, and many pharma stocks are ...